Ally Olotu/Lancet

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS Dicko A Tinto H Ouedraogo JB Hamaluba M Olotu A Beaumont E Ramos Lopez F Natama HM Weston S Chemba M Compaore YD Issiaka D Salou D Some AM Omenda S Lawrie A Bejon P Rao H Chandramohan D Roberts R Bharati S Stockdale L Gairola S Greenwood BM Ewer KJ Bradley J Kulkarni PS Shaligram U Hill AVS R1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544